TrialSite News podcast: Patient recruitment challenges for COVID-19 clinical trials

February 8, 2021
“It’s HARD to find patients for clinical trials”, Claudia Christian, Senior Vice President, Clinical Operations at FHI Clinical, told Adrian Houser of TrialSite News in a recent sit-down about COVID-19 vaccine trials. “However, decades of conducting complex clinical research in resource-limited settings have taught us a few tricks,” says Claudia.
She explains that FHI Clinical starts by hiring a very diverse workforce—diverse in race, gender, culture, life experiences and geography. This diversity helps FHI Clinical recruit patients from around the world, ensuring a more varied and representative trial population and bringing the opportunity to participate in trials to underserved areas in the world. As a result, trials are better populated, the data is richer and sponsors are able to bring high-quality treatments to market faster.

Learn more about how FHI Clinical is solving patient recruitment and other challenges by listening to the full interview here.

news archive

Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

September 7, 2022
The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.

Read more »

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022
FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Read more »

Share this post